NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport

Neurobiology of Disease

Volumn 56, Issue , 2013, Pages 79-94

  Jouroukhin, Yan ^a   Ostritsky, Regina ^a   Assaf, Yaniv ^a   Pelled, Galit ^b,c   Giladi, Eliezer ^a   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALS; Axonal transport; MRI; NAP (davunetide); SOD1; SOD1 G93A; Spinal cord; Transgenic mice (Tg); Ventral tegmental area (VTA)

Indexed keywords

DAVUNETIDE; MANGANESE; TAU PROTEIN;

ACUTE DRUG ADMINISTRATION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HISTOCHEMISTRY; HISTOPATHOLOGY; IN VIVO STUDY; LIFESPAN; LOW DRUG DOSE; MALE; MOUSE; NERVE CELL NETWORK; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; WILD TYPE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AXONAL TRANSPORT; BLOTTING, WESTERN; BODY WEIGHT; BRAIN; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; MICE; MICE, INBRED C57BL; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; PHOSPHORYLATION; PSYCHOMOTOR PERFORMANCE; SPINAL CORD; TAU PROTEINS; TUBULIN; TYROSINE; VENTRAL TEGMENTAL AREA;

EID: 84877914479     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.04.012     Document Type: Article

References (114)

1. Alcalay R.N., Giladi E., Pick C.G., Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 2004, 361:128-131.
2. Atzori M., Kanold P., Pineda J.C., Flores-Hernandez J. Dopamine-acetylcholine interactions in the modulation of glutamate release. Ann. N. Y. Acad. Sci. 2003, 1003:346-348.
3. Atzori M., Kanold P.O., Pineda J.C., Flores-Hernandez J., Paz R.D. Dopamine prevents muscarinic-induced decrease of glutamate release in the auditory cortex. Neuroscience 2005, 134:1153-1165.
4. Barten D.M., Fanara P., Andorfer C., Hoque N., Wong P.Y., Husted K.H., Cadelina G.W., Decarr L.B., Yang L., Liu V., Fessler C., Protassio J., Riff T., Turner H., Janus C.G., Sankaranarayanan S., Polson C., Meredith J.E., Gray G., Hanna A., Olson R.E., Kim S.H., Vite G.D., Lee F.Y., Albright C.F. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J. Neurosci. 2012, 32:7137-7145.
5. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., Bassan H., Blat C., Gibney G., Glazner G., Brenneman D.E., Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 1999, 72:1283-1293.
6. Beaulieu J.M., Nguyen M.D., Julien J.P. Late onset of motor neurons in mice overexpressing wild-type peripherin. J. Cell Biol. 1999, 147:531-544.
7. Bertrand A., Khan U., Hoang D.M., Novikov D.S., Krishnamurthy P., Rajamohamed Sait H.B., Little B.W., Sigurdsson E.M., Wadghiri Y.Z. Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRI. NeuroImage 2013, 64:693-702.
8. Blumenfeld-Katzir T., Pasternak O., Dagan M., Assaf Y. Diffusion MRI of structural brain plasticity induced by a learning and memory task. PLoS One 2011, 6:e20678.
9. Brunig I., Sommer M., Hatt H., Bormann J. Dopamine receptor subtypes modulate olfactory bulb gamma-aminobutyric acid type A receptors. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2456-2460.
10. Bucher S., Braunstein K.E., Niessen H.G., Kaulisch T., Neumaier M., Boeckers T.M., Stiller D., Ludolph A.C. Vacuolization correlates with spin-spin relaxation time in motor brainstem nuclei and behavioural tests in the transgenic G93A-SOD1 mouse model of ALS. Eur. J. Neurosci. 2007, 26:1895-1901.
11. Chan K.C., Cheng J.S., Fan S., Zhou I.Y., Wu E.X. In vivo manganese-enhanced MRI and diffusion tensor imaging of developing and impaired visual brains. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2011, 2011:7005-7008.
12. Chan K.C., Li J., Kau P., Zhou I.Y., Cheung M.M., Lau C., Yang J., So K.F., Wu E.X. In vivo retinotopic mapping of superior colliculus using manganese-enhanced magnetic resonance imaging. NeuroImage 2011, 54:389-395.
13. Chan K.C., Cheng J.S., Fan S., Zhou I.Y., Yang J., Wu E.X. In vivo evaluation of retinal and callosal projections in early postnatal development and plasticity using manganese-enhanced MRI and diffusion tensor imaging. NeuroImage 2012, 59:2274-2283.
14. Cross D.J., Flexman J.A., Anzai Y., Maravilla K.R., Minoshima S. Age-related decrease in axonal transport measured by MR imaging in vivo. NeuroImage 2008, 39:915-926.
15. Di Salvio M., Di Giovannantonio L.G., Acampora D., Prosperi R., Omodei D., Prakash N., Wurst W., Simeone A. Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. Nat. Neurosci. 2010, 13:1481-1488.
16. Di Salvio M., Di Giovannantonio L.G., Omodei D., Acampora D., Simeone A. Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. Int. J. Dev. Biol. 2010, 54:939-945.
17. Divinski I., Mittelman L., Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J. Biol. Chem. 2004, 279:28531-28538.
18. Divinski I., Holtser-Cochav M., Vulih-Schultzman I., Steingart R.A., Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J. Neurochem. 2006, 98:973-984.
19. Dresner E., Agam G., Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur. Neuropsychopharmacol. 2011, 21:355-361.
20. Farah C.A., Nguyen M.D., Julien J.P., Leclerc N. Altered levels and distribution of microtubule-associated proteins before disease onset in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2003, 84:77-86.
21. Ferrucci M., Pasquali L., Paparelli A., Ruggieri S., Fornai F. Pathways of methamphetamine toxicity. Ann. N. Y. Acad. Sci. 2008, 1139:177-185.
22. Ferrucci M., Spalloni A., Bartalucci A., Cantafora E., Fulceri F., Nutini M., Longone P., Paparelli A., Fornai F. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium. Neurobiol. Dis. 2010, 37:370-383.
23. Fischer D., Mukrasch M.D., Biernat J., Bibow S., Blackledge M., Griesinger C., Mandelkow E., Zweckstetter M. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules. Biochemistry 2009, 48:10047-10055.
24. Gallagher J.J., Zhang X., Ziomek G.J., Jacobs R.E., Bearer E.L. Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI. NeuroImage 2012, 60:1856-1866.
25. Gold M., Lorenzl S., Stewart A.J., Morimoto B.H., Williams D.R., Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr. Dis. Treat. 2012, 8:85-93.
26. Gozes I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr. Pharm. Des. 2011, 17:3413-3417.
27. Gozes I. NAP (davunetide) provides functional and structural neuroprotection. Curr. Pharm. Des. 2011, 17:1040-1044.
28. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 2000, 293:1091-1098.
29. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D.E., Spier A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci. 2003, 20:315-322.
30. Gozes I., Morimoto B.H., Tiong J., Fox A., Sutherland K., Dangoor D., Holser-Cochav M., Vered K., Newton P., Aisen P.S., Matsuoka Y., van Dyck C.H., Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005, 11:353-368.
31. Gozes I., Stewart A., Morimoto B., Fox A., Sutherland K., Schmechel D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr. Alzheimer Res. 2009, 6:455-460.
32. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
33. Haenold R., Herrmann K.H., Schmidt S., Reichenbach J.R., Schmidt K.F., Lowel S., Witte O.W., Weih F., Kretz A. Magnetic resonance imaging of the mouse visual pathway for in vivo studies of degeneration and regeneration in the CNS. NeuroImage 2012, 59:363-376.
34. Holtser-Cochav M., Divinski I., Gozes I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J. Mol. Neurosci. 2006, 28:303-307.
35. Idan-Feldman A., Schirer Y., Polyzoidou E., Touloumi O., Lagoudaki R., Grigoriadis N.C., Gozes I. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol. Dis. 2011, 44:327-339.
36. Idan-Feldman A., Ostritsky R., Gozes I. Tau and caspase 3 as targets for neuroprotection. Int. J. Alzheimers Dis. 2012, 2012:493670.
37. Iijima-Ando K., Sekiya M., Maruko-Otake A., Ohtake Y., Suzuki E., Lu B., Iijima K.M. Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1. PLoS Genet. 2012, 8:e1002918.
38. Inoue T., Majid T., Pautler R.G. Manganese enhanced MRI (MEMRI): neurophysiological applications. Rev. Neurosci. 2011, 22:675-694.
39. Jarskog L.F., Dong Z., Kangarlu A., Colibazzi T., Girgis R.R., Kegeles L.S., Barch D.M., Buchanan R.W., Csernansky J.G., Goff D.C., Harms M.P., Javitt D.C., Keefe R.S., McEvoy J.P., McMahon R.P., Marder S.R., Peterson B.S., Lieberman J.A. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 2013, (Electronic publication ahead of print). 10.1038/npp.2013.23.
40. Javitt D.C., Buchanan R.W., Keefe R.S., Kern R., McMahon R.P., Green M.F., Lieberman J., Goff D.C., Csernansky J.G., McEvoy J.P., Jarskog F., Seidman L.J., Gold J.M., Kimhy D., Nolan K.S., Barch D.S., Ball M.P., Robinson J., Marder S.R. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 2012, 136:25-31.
41. Johnson M.L., Day A.E., Ho C.C., Walker Q.D., Francis R., Kuhn C.M. Androgen decreases dopamine neurone survival in rat midbrain. J. Neuroendocrinol. 2010, 22:238-247.
42. Jouroukhin Y., Ostritsky R., Gozes I. D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J. Mol. Neurosci. 2012, 48:597-602.
43. Joyce P.I., Fratta P., Fisher E.M., Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome 2011, 22:420-448.
44. Kandinov B., Korczyn A.D., Rabinowitz R., Nefussy B., Drory V.E. Autonomic impairment in a transgenic mouse model of amyotrophic lateral sclerosis. Auton. Neurosci. 2011, 159:84-89.
45. Kitahama K., Nagatsu I., Geffard M., Maeda T. Distribution of dopamine-immunoreactive fibers in the rat brainstem. J. Chem. Neuroanat. 2000, 18:1-9.
46. Koos B.J., Kawasaki Y., Hari A., Bohorquez F., Jan C., Roostaeian J., Wilson C.L., Kruger L. Electrical stimulation of the posteromedial thalamus modulates breathing in unanesthetized fetal sheep. J. Appl. Physiol. 2004, 96:115-123.
47. Kostic V., Gurney M.E., Deng H.X., Siddique T., Epstein C.J., Przedborski S. Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann. Neurol. 1997, 41:497-504.
48. Kuzma-Kozakiewicz M., Usarek E., Ludolph A.C., Baranczyk-Kuzma A. Mice with mutation in dynein heavy chain 1 do not share the same tau expression pattern with mice with SOD1-related motor neuron disease. Neurochem. Res. 2011, 36:978-985.
49. Lee H.J., Yoo S.J., Lee S., Song H.J., Huh M.I., Jin S.U., Lee K.Y., Lee J., Cho J.H., Chang Y. Functional activity mapping of rat auditory pathway after intratympanic manganese administration. NeuroImage 2012, 60:1046-1054.
50. Lei P., Ayton S., Finkelstein D.I., Spoerri L., Ciccotosto G.D., Wright D.K., Wong B.X., Adlard P.A., Cherny R.A., Lam L.Q., Roberts B.R., Volitakis I., Egan G.F., McLean C.A., Cappai R., Duce J.A., Bush A.I. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 2012, 18:291-295.
51. Leker R.R., Teichner A., Grigoriadis N., Ovadia H., Brenneman D.E., Fridkin M., Giladi E., Romano J., Gozes I. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 2002, 33:1085-1092.
52. Lodge D.J., Grace A.A. The laterodorsal tegmentum is essential for burst firing of ventral tegmental area dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5167-5172.
53. Lu C.H., Petzold A., Kalmar B., Dick J., Malaspina A., Greensmith L. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS. PLoS One 2012, 7:e40998.
54. Ludolph A.C., Bendotti C., Blaugrund E., Hengerer B., Loffler J.P., Martin J., Meininger V., Meyer T., Moussaoui S., Robberecht W., Scott S., Silani V., Van Den Berg L.H. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph. Lateral Scler. 2007, 8:217-223.
55. Luo C., Chen Q., Huang R., Chen X., Chen K., Huang X., Tang H., Gong Q., Shang H.F. Patterns of spontaneous brain activity in amyotrophic lateral sclerosis: a resting-state FMRI study. PLoS One 2012, 7:e45470.
56. Mandel S., Rechavi G., Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev. Biol. 2007, 303:814-824.
57. Mandell J.G., Neuberger T., Drapaca C.S., Webb A.G., Schiff S.J. The dynamics of brain and cerebrospinal fluid growth in normal versus hydrocephalic mice. J. Neurosurg. Pediatr. 2010, 6:1-10.
58. Martirosyan N.L., Bennett K.M., Theodore N., Preul M.C. Manganese-enhanced magnetic resonance imaging in experimental spinal cord injury: correlation between T1-weighted changes and Mn(2+) concentrations. Neurosurgery 2010, 66:131-136.
59. Massaad C.A., Pautler R.G. Manganese-enhanced magnetic resonance imaging (MEMRI). Methods Mol. Biol. 2011, 711:145-174.
60. Matsuda K., Wang H.X., Suo C., McCombe D., Horne M.K., Morrison W.A., Egan G.F. Retrograde axonal tracing using manganese enhanced magnetic resonance imaging. NeuroImage 2010, 50:366-374.
61. Matsukawa K., Nakamoto T., Liang N. Electrical stimulation of the mesencephalic ventral tegmental area evokes skeletal muscle vasodilatation in the cat and rat. J. Physiol. Sci. 2011, 61:293-301.
62. Matsuoka Y., Gray A.J., Hirata-Fukae C., Minami S.S., Waterhouse E.G., Mattson M.P., LaFerla F.M., Gozes I., Aisen P.S. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J. Mol. Neurosci. 2007, 31:165-170.
63. Matsuoka Y., Jouroukhin Y., Gray A.J., Ma L., Hirata-Fukae C., Li H.F., Feng L., Lecanu L., Walker B.R., Planel E., Arancio O., Gozes I., Aisen P.S. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 2008, 325:146-153.
64. Merenlender-Wagner A., Pikman R., Giladi E., Andrieux A., Gozes I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubule-deficient model of schizophrenia. Peptides 2010, 31:1368-1373.
65. Miana-Mena F.J., Munoz M.J., Yague G., Mendez M., Moreno M., Ciriza J., Zaragoza P., Osta R. Optimal methods to characterize the G93A mouse model of ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2005, 6:55-62.
66. Mooney K.E., Inokuchi A., Snow J.B., Kimmelman C.P. Projections from the ventral tegmental area to the olfactory tubercle in the rat. Otolaryngol. Head Neck Surg. 1987, 96:151-157.
67. Ngo S.T., Baumann F., Ridall P.G., Pettitt A.N., Henderson R.D., Bellingham M.C., McCombe P.A. The relationship between Bayesian motor unit number estimation and histological measurements of motor neurons in wild-type and SOD1(G93A) mice. Clin. Neurophysiol. 2012, 123:2080-2091.
68. Nishitoh H., Kadowaki H., Nagai A., Maruyama T., Yokota T., Fukutomi H., Noguchi T., Matsuzawa A., Takeda K., Ichijo H. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 2008, 22:1451-1464.
69. Oades R.D., Halliday G.M. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res. 1987, 434:117-165.
70. Obenaus A., Jacobs R.E. Magnetic resonance imaging of functional anatomy: use for small animal epilepsy models. Epilepsia 2007, 48(Suppl. 4):11-17.
71. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D.E., Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 2000, 854:257-262.
72. Omelchenko N., Sesack S.R. Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area. J. Comp. Neurol. 2005, 483:217-235.
73. Oz S., Ivashko-Pachima Y., Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One 2013, 7(12):e51458. (Electronic publication ahead of print, 2012 Dec 14). 10.1371/journal.pone.0051458.
74. Park J., Chung S., An H., Kim J., Seo J., Kim D.H., Yoon S.Y. Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons. Neuroscience 2012, 209:64-73.
75. Pautler R.G. In vivo, trans-synaptic tract-tracing utilizing manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed. 2004, 17:595-601.
76. Pautler R.G., Koretsky A.P. Tracing odor-induced activation in the olfactory bulbs of mice using manganese-enhanced magnetic resonance imaging. NeuroImage 2002, 16:441-448.
77. Pinhasov A., Mandel S., Torchinsky A., Giladi E., Pittel Z., Goldsweig A.M., Servoss S.J., Brenneman D.E., Gozes I. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 2003, 144:83-90.
78. Quraishe S., Cowan C.M., Mudher A. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol. Psychiatry 2013, (in press) (Electronic publication ahead of print). 10.1038/mp.2013.32.
79. Ragonese P., Cellura E., Aridon P., D'Amelio M., Spataro R., Taiello A.C., Maimone D., La Bella V., Savettieri G. Incidence of amyotrophic lateral sclerosis in Sicily: a population based study. Amyotroph. Lateral Scler. 2012, 13:284-287.
80. Rukhadze I., Kubin L. Mesopontine cholinergic projections to the hypoglossal motor nucleus. Neurosci. Lett. 2007, 413:121-125.
81. Saragoni L., Hernandez P., Maccioni R.B. Differential association of tau with subsets of microtubules containing posttranslationally-modified tubulin variants in neuroblastoma cells. Neurochem. Res. 2000, 25:59-70.
82. Schaeffer V., Lavenir I., Ozcelik S., Tolnay M., Winkler D.T., Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 2012, 135:2169-2177.
83. Scott S., Kranz J.E., Cole J., Lincecum J.M., Thompson K., Kelly N., Bostrom A., Theodoss J., Al-Nakhala B.M., Vieira F.G., Ramasubbu J., Heywood J.A. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008, 9:4-15.
84. Sesack S.R., Carr D.B., Omelchenko N., Pinto A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann. N. Y. Acad. Sci. 2003, 1003:36-52.
85. Sharma R., Buras E., Terashima T., Serrano F., Massaad C.A., Hu L., Bitner B., Inoue T., Chan L., Pautler R.G. Hyperglycemia induces oxidative stress and impairs axonal transport rates in mice. PLoS One 2010, 5:e13463.
86. 1H MRS of basal ganglia and thalamus in amyotrophic lateral sclerosis. NMR Biomed. 2011, 24:1270-1276.
87. Shiryaev N., Jouroukhin Y., Giladi E., Polyzoidou E., Grigoriadis N.C., Rosenmann H., Gozes I. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol. Dis. 2009, 34:381-388.
88. Shughrue P.J. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta). Exp. Neurol. 2004, 190:468-477.
89. Smidt M.P., Burbach J.P. How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 2007, 8:21-32.
90. Smith K.D., Kallhoff V., Zheng H., Pautler R.G. In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. NeuroImage 2007, 35:1401-1408.
91. Smith K.D., Peethumnongsin E., Lin H., Zheng H., Pautler R.G. Increased human wildtype tau attenuates axonal transport deficits caused by loss of APP in mouse models. Magn. Reson. Insights 2010, 4:11-18.
92. Smith K.D., Paylor R., Pautler R.G. R-flurbiprofen improves axonal transport in the Tg2576 mouse model of Alzheimer's disease as determined by MEMRI. Magn. Reson. Med. 2011, 65:1423-1429.
93. Steingart R.A., Solomon B., Brenneman D.E., Fridkin M., Gozes I. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci. 2000, 15:137-145.
94. Stommel E.W., Graber D., Montanye J., Cohen J.A., Harris B.T. Does treating schizophrenia reduce the chances of developing amyotrophic lateral sclerosis?. Med. Hypotheses 2007, 69:1021-1028.
95. Strong M.J. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2008, 9:323-338.
96. Sudo H., Baas P.W. Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. Hum. Mol. Genet. 2011, 20:763-778.
97. Taes I., Goris A., Lemmens R., van Es M.A., van den Berg L.H., Chio A., Traynor B.J., Birve A., Andersen P., Slowik A., Tomik B., Brown R.H., Shaw C.E., Al-Chalabi A., Boonen S., Van Den Bosch L., Dubois B., Van Damme P., Robberecht W. Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse. Neurology 2010, 74:1687-1693.
98. Thuen M., Berry M., Pedersen T.B., Goa P.E., Summerfield M., Haraldseth O., Sandvig A., Brekken C. Manganese-enhanced MRI of the rat visual pathway: acute neural toxicity, contrast enhancement, axon resolution, axonal transport, and clearance of Mn(2+). J. Magn. Reson. Imaging 2008, 28:855-865.
99. Turner B.J., Rembach A., Spark R., Lopes E.C., Cheema S.S. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. J. Neurosci. Res. 2003, 74:605-613.
100. Van den Heuvel D.M., Pasterkamp R.J. Getting connected in the dopamine system. Prog. Neurobiol. 2008, 85:75-93.
101. Venkova-Hristova K., Christov A., Kamaluddin Z., Kobalka P., Hensley K. Progress in therapy development for amyotrophic lateral sclerosis. Neurol. Res. Int. 2012, 2012:187234.
102. Vinayagam A., Stelzl U., Foulle R., Plassmann S., Zenkner M., Timm J., Assmus H.E., Andrade-Navarro M.A., Wanker E.E. A directed protein interaction network for investigating intracellular signal transduction. Sci. Signal. 2011, 4:rs8.
103. Vulih-Shultzman I., Pinhasov A., Mandel S., Grigoriadis N., Touloumi O., Pittel Z., Gozes I. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 2007, 323:438-449.
104. Wang F.H., Appelkvist P., Klason T., Gissberg O., Bogstedt A., Eliason K., Martinsson S., Briem S., Andersson A., Visser S.A., Ivarsson M., Lindberg M., Agerman K., Sandin J. Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma-secretase inhibitor MRK-560 as detected by manganese-enhanced MRI. Eur. J. Neurosci. 2012, 36:3165-3172.
105. Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18809-18814.
106. Wu J., Dang Y., Su W., Liu C., Ma H., Shan Y., Pei Y., Wan B., Guo J., Yu L. Molecular cloning and characterization of rat LC3A and LC3B-two novel markers of autophagosome. Biochem. Biophys. Res. Commun. 2006, 339:437-442.
107. Wu C.H., Fallini C., Ticozzi N., Keagle P.J., Sapp P.C., Piotrowska K., Lowe P., Koppers M., McKenna-Yasek D., Baron D.M., Kost J.E., Gonzalez-Perez P., Fox A.D., Adams J., Taroni F., Tiloca C., Leclerc A.L., Chafe S.C., Mangroo D., Moore M.J., Zitzewitz J.A., Xu Z.S., van den Berg L.H., Glass J.D., Siciliano G., Cirulli E.T., Goldstein D.B., Salachas F., Meininger V., Rossoll W., Ratti A., Gellera C., Bosco D.A., Bassell G.J., Silani V., Drory V.E., Brown R.H., Landers J.E. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012, 488:499-503.
108. Yang W., Strong M.J. Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment. Amyotroph. Lateral Scler. 2012, 13:178-193.
109. Yang P.F., Chen D.Y., Hu J.W., Chen J.H., Yen C.T. Functional tracing of medial nociceptive pathways using activity-dependent manganese-enhanced MRI. Pain 2011, 152:194-203.
110. Zang D.W., Yang Q., Wang H.X., Egan G., Lopes E.C., Cheema S.S. Magnetic resonance imaging reveals neuronal degeneration in the brainstem of the superoxide dismutase 1 transgenic mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2004, 20:1745-1751.
111. Zemlyak I., Furman S., Brenneman D.E., Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regul. Pept. 2000, 96:39-43.
112. Zemlyak I., Manley N., Sapolsky R., Gozes L. NAP protects hippocampal neurons against multiple toxins. Peptides 2007, 28:2004-2008.
113. Zemlyak I., Sapolsky R., Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur. J. Pharmacol. 2009, 618:9-14.
114. Zhang B., Carroll J., Trojanowski J.Q., Yao Y., Iba M., Potuzak J.S., Hogan A.M., Xie S.X., Ballatore C., Smith A.B., Lee V.M., Brunden K.R. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 2012, 32:3601-3611.